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Langerhans cells (LCs) constitute a subset of 
DCs. In their immature state, they reside in the 
stratified squamous epidermal layer of the skin 
and in the mucosal epithelia lining the ocular, 
oral, and vaginal surfaces (Iwasaki, 2007). LCs 
have long been regarded as the exclusive APCs 
of the skin, detecting pathogens that penetrate 
the skin barrier and, after undergoing a phase of 
maturation,  conveying  this  information  via 
lymphatic vessels to T cells present in cutaneous 
LNs (CLNs; Steinman and Nussenzweig, 2002; 
Larregina and Falo, 2005). Recent studies have 
shown, however, that LCs do not constitute the 
exclusive APCs of the skin. In addition to LCs, 
the skin contains a second type of DCs known 
as  dermal  DCs  (DDCs).  Epidermal  LCs  and 
DDCs migrate to CLNs under both steady-
state and inflammatory conditions and consti-
tute the direct precursors of the migratory LCs 
(mLCs) and migratory DDCs (mDDCs) found 
in CLNs, respectively. Some studies also sug-
gested that migratory skin DCs play an indirect 
role in T cell priming, possibly by ferrying skin-
derived  antigens  to  those  DCs  that  reside 
throughout their life cycle in CLNs and are de-
noted as lymphoid tissue–resident DCs to dis-
tinguish  them  from  tissue-derived  migratory 
DCs (Allan et al., 2003; Carbone et al., 2004; 
Allenspach et al., 2008).
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Recent studies have challenged the view that Langerhans cells (LCs) constitute the exclusive 
antigen-presenting cells of the skin and suggest that the dermal dendritic cell (DDC) net-
work is exceedingly complex. Using knockin mice to track and ablate DCs expressing lan-
gerin (CD207), we discovered that the dermis contains five distinct DC subsets and 
identified their migratory counterparts in draining lymph nodes. Based on this refined 
classification, we demonstrated that the quantitatively minor CD207+ CD103+ DDC subset is 
endowed with the unique capability of cross-presenting antigens expressed by keratinocytes 
irrespective of the presence of LCs. We further showed that Y-Ae, an antibody that is 
widely used to monitor the formation of complexes involving I-Ab molecules and a peptide 
derived from the I-E  chain, recognizes mature skin DCs that express I-Ab molecules in the 
absence of I-E . Knowledge of this extra reactivity is important because it could be, and 
already has been, mistakenly interpreted to support the view that antigen transfer can 
occur between LCs and DDCs. Collectively, these data revisit the transfer of antigen that 
occurs between keratinocytes and the five distinguishable skin DC subsets and stress the 
high degree of functional specialization that exists among them.
© 2010 Henri et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons.
org/licenses/by-nc-sa/3.0/).
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DC subsets based on their differential ability to respond to 
CCL21 (Nagao et al., 2009). To circumvent these limita-
tions, the epidermis of C57BL/6 mice was separated from the 
dermis using dispase treatment and the DCs associated with 
each compartment were extracted using collagenase diges-
tion.  CD11c  expression  is  generally  used  to  define  DCs. 
However,  collagenase  and  dispase  digestion  tend  to  affect 
CD11c expression, whereas MHCII expression was insensi-
tive to such treatment. Therefore, after exclusion of rare au-
tofluorescent cells (primarily macrophages; Ng et al., 2008), 
MHCIIhigh cells present in epidermal and dermal cell suspen-
sions were analyzed for CD11b and CD207 expression. The 
epidermis contained a single homogeneous CD207high CD-
11bint DC population that did not express the integrin E 
chain (CD103) and corresponds to LCs (Fig. 1 A). Among 
the MHCIIhigh cells present in the dermis, four DC subsets 
were distinguished based on their CD207high CD11bint, CD207+ 
CD11blow, CD207 CD11b, and CD207 CD11b+ phe-
notype (Fig. 1 A).
LCs are radio resistant and, thus, differ from the radio-
sensitive BM-derived precursors that continuously renew the 
DDC pool (Merad et al., 2002). This distinct sensitivity to 
radiation was used to determine which subset among the two 
CD207+ DDC subsets corresponded to epidermal mLCs en 
route  to  the  CLNs.  Accordingly,  lethally  irradiated  B6 
(CD45.2) mice were reconstituted with BM cells isolated 
from B6 (CD45.1) mice. Analysis of those chimeras, called 
B6 (CD45.1)→B6 (CD45.2) chimeras, 8 wk after BM trans-
plantation showed that the CD207high CD11bint DC subset 
present in the dermis was entirely of host origin and thus cor-
responded to mLCs (Fig. 1 B, middle; and Fig. S1), whereas 
the CD207+ CD11blow DC subset was of donor origin and 
corresponded to CD207+ DDCs (Fig. 1 B). Despite com-
plete donor chimerism, as assessed using blood B cells, we 
sporadically found that, in some chimeras, up to 4% of the 
DDCs remained of host origin (Fig. 1 B, middle). Therefore, 
as recently suggested (Bogunovic et al., 2006), a small num-
ber of DDCs is likely regenerated by local radio-resistant pre-
cursors. Within cells of donor origin, two subsets of DDCs 
can be distinguished in addition to the CD207+ CD11blow 
subset,  and  they  correspond  to  CD207  CD11b+  and 
CD207 CD11b DDCs (Fig. 1 B). Among the four DC 
subsets present in the dermis, CD103 was expressed on ap-
proximately half of the CD207+ CD11blow DDCs (Fig. 1 C). 
Therefore, contrary to a previous study suggesting that the 
whole CD207+ CD11blow DDC subset expresses CD103 and 
that such a feature can be used to distinguish CD207+ DDCs 
from both mLCs and CD207 DDCs (Bursch et al., 2007), 
our results demonstrate that CD103 expression alone cannot 
be used to identify CD207+ DDCs because only half of them 
express such a marker.
Consistent with a recent study (Nagao et al., 2009), the 
putative cell adhesion molecule epithelial cell adhesion mol-
ecule (EpCAM; CD326) was found to be highly expressed 
by LCs. Both the CD207+ CD103+ and CD207+ CD103 
DDC subsets also expressed EpCAM but at lower levels than 
Langerin (CD207) is a C-type lectin originally thought   
to be specifically expressed in LCs (Valladeau et al., 2000;   
Kissenpfennig et al., 2005a). The use of Lang-EGFP mice that 
express an enhanced GFP (EGFP) under the control of the 
langerin gene showed that CD207 alone is not a reliable marker 
for the identification of LCs once they have migrated outside 
the epidermis (Kissenpfennig et al., 2005b) and led to the 
identification of three subsets of CD207+ DCs in steady-state 
CLNs (Bursch et al., 2007; Ginhoux et al., 2007; Poulin et al., 
2007; Shklovskaya et al., 2008). A minor subset corresponds to 
lymphoid tissue–resident CD207low CD8+ DCs and repre-
sents 10% of the CD207+ DCs found in CLNs. The two 
other subsets account for 90% of the CD207+ cells present in 
CLNs and, consistent with their CD11cinter-to-high MHCIIhigh 
phenotype, originate from the skin. They result from two in-
dependent developmental pathways that coexist in steady-state 
conditions. The first pathway gives rise to epidermal LCs and 
to their migratory derivatives found in CLNs, whereas the sec-
ond pathway generates the CD207+ DCs that reside in the 
dermis  and  their  CD207+  mDDC  progeny  (Bursch  et  al., 
2007; Ginhoux et al., 2007; Poulin et al., 2007; Shklovskaya et 
al., 2008). LCs are radio resistant, and their numbers are main-
tained through continuous in situ proliferation (Merad et al., 
2002; Tripp et al., 2004; Poulin et al., 2007). In contrast, the 
continuous renewal of DDCs and of lymphoid tissue-resident 
DCs depends on blood-borne radiosensitive BM precursors 
(Liu et al., 2009). As a consequence, in lethally irradiated mice 
reconstituted with BM transplants, LCs in the epidermis and 
their migratory counterparts in the dermis and CLNs remain 
of host origin, whereas other DC subsets are primarily repopu-
lated by donor BM–derived cells (Merad et al., 2002).
The role played by LCs and DDCs during skin immune 
responses remains controversial (Kaplan et al., 2008; Lee et al., 
2009). Therefore, the present study intends to further analyze 
the phenotypic and functional complexity of the DC network 
present in the skin and of their migratory derivatives present 
in CLNs. Based on the expression of CD207, CD11b, and 
CD103, we identified five distinct skin DC subsets and evalu-
ated  whether  some  functional  specialization  exists  among 
them. We examined the contribution of each of them to the 
presentation of keratinocyte- or LC-expressed antigens. We 
demonstrated  that  CD207+  CD103+  DDCs  are  endowed 
with the unique capability of cross-presenting a model anti-
gen expressed by keratinocytes and showed that such a task 
can be accomplished irrespective of the presence of LCs. In 
contrast to a previous study (Ginhoux et al., 2007), we also 
demonstrated that DDCs do not have the capacity to capture 
a model antigen carried by mLCs en route to the CLNs.
RESULTS
Five distinct DC subsets coexist in steady-state dermis
We previously characterized the DCs that migrate out of 
whole skin explants in response to the CCL21 chemokine 
(Poulin et al., 2007). However, this approach does not permit 
us to establish the epidermal or dermal origin of the migratory 
DCs and likely distorts the representation of the various skin JEM VOL. 207, January 18, 2010 
Article
191
Figure 1.  The skin contains five distinguishable DC subsets. Flow cytometry analysis of epidermal and dermal cell suspensions from C57BL/6 (B6) 
and B6 (CD45.1)→B6 (CD45.2) BM chimeras. After gating out autofluorescent cells using the AmCyan channel (den Haan et al., 2000; Wilson et al., 2003), 
MHCII+ cells were analyzed for expression of langerin (CD207) versus CD11b, and CD103 expression was determined on each of the specified DC subsets. 
(A) In B6 mice, the epidermis contains CD207high CD11bint LCs that are CD103 and the dermis contains four DC subsets that can be distinguished on the 
basis of CD11b and CD207 expression. (B) DCs found in the dermis of B6 (CD45.1)→B6 (CD45.2) BM chimeras were segregated into host-derived and 
donor-derived cells using CD45.1 staining (Fig. S1). Host-derived CD45.1 CD207high CD11bint cells correspond to mLCs that are in transit to CLNs. Donor-
derived CD45.1+ DDCs segregate into CD207+ CD11blow, CD207 CD11b+, and CD207 CD11b subsets. (C) Analysis of the expression of CD103 on the four 
DC subsets present in the dermis showed that it is only expressed on a fraction of the CD207+ CD11blow subset and thus allows us to define five skin DC 
subsets. The percentages of cells found in each of the specified gates are indicated. Data shown are representative of at least 12 chimeric mice corre-
sponding to six independent experiments.192 Function of skin DC subsets | Henri et al.
Figure 2.  Expression of EpCAM, CD24, F4/80, and SIRP on the five skin DC subsets before and after their migration to CLNs. DC subsets 
were prepared as specified in Figs. 1 and 3 from dermis and CLNs from B6 (CD45.1)→B6 (CD45.2) BM chimeras and analyzed for the expression of Ep-
CAM, CD24, F4/80, and SIRP. Isotype control staining is shown by the shaded histograms. In steady-state skin, LCs and CD207 CD11b+ DDCs were ho-
mogeneously F4/80+. CD207 CD11b DDCs showed a heterogeneous pattern of F4/80 expression, whereas both subsets of CD207+ DDCs were F4/80. JEM VOL. 207, January 18, 2010 
Article
193
LCs (Fig. 2). As recently described (Stutte et al., 2008), CD24 
expression correlated with CD207 expression and was thus 
highly expressed by both the LCs and CD207+ DDC subsets 
(Fig. 2). As summarized in Table I, five distinct subsets can 
thus be identified in steady-state dermis using the CD207, 
CD11b, and CD103 markers. CD207 CD11b+ (65.8 ± 5%) 
and CD207 CD11b (16.3 ± 1.3%) DDCs constitute the 
majority of the DCs found in steady-state dermis, whereas 
CD207+ CD103 (2.8 ± 0.5%) and CD207+ CD103+ (2.6 ± 
0.6%) DDCs represent quantitatively minor populations of 
DDCs. Finally, mLCs en route to the CLNs corresponded to 
6.4 ± 2% of the DCs found in the dermis.
Five skin-derived DC subsets coexist in steady-state CLNs
After migration to CLNs, skin-derived DCs increase the lev-
els of MHCII molecules that they express at their surface and 
can be identified as MHCIIhigh CD11cinter-to-high cells (Dakic 
et al., 2004; Kissenpfennig et al., 2005b). When MHCIIhigh 
CD11cinter-to-high skin-derived DCs were analyzed for the ex-
pression  of  CD207  and  CD11b,  CD207  CD11b+  and 
CD207 CD11b mDDC clusters were readily identified 
(Fig. 3 A). However, in contrast to the situation observed in 
the dermis, CD11b did not allow discrimination of CD207+ 
skin-derived DCs into CD11bint and a CD11blow clusters.   
Instead, a single CD207+ CD11b/low cluster was found and 
analysis of B6 (CD45.1)→B6 (CD45.2) BM chimeras showed 
that  this  cluster  contained  both  radio-resistant  mLCs  and   
radio-sensitive CD207+ mDDCs (Fig. 3 A). Akin to their der-
mal counterparts, the radio-sensitive CD207+ mDDCs were 
CD11blow and could be further segregated into CD103+ and 
CD103 subsets (Fig. 3 B). As described in the last Results 
section, after in vivo diphtheria toxin (DT) treatment of Lang-
DTREGFP mice, LCs and CD207+ DDCs repopulate the 
skin with different kinetics, and it is thus possible to obtain 
mice that are deprived of LCs but contain a fully reconsti-
tuted CD207+ DDC compartment in both the dermis and 
the CLNs. Analysis of the CD207+ DDCs present in both the 
dermis and the CLNs of those LC-less mice showed that they 
are made of CD103+ and CD103 fractions, the frequency of 
which is similar to that found in mice that contain a normal 
LC compartment (Fig. S2). Therefore, the CD207+ CD103 
DDCs do not result from the contamination of the CD207+ 
DDC subset by CD207+ CD103 mLCs. When compared 
with mLCs in transit in the dermis, the mLCs found in CLNs 
showed down-regulated levels of CD11b (Fig. 3 A), and it is 
this decrease in CD11b expression that prevented the dis-
crimination  of  mLCs  from  CD207+  mDDCs. Therefore, 
analysis of the CLNs of B6 (CD45.1)→B6 (CD45.2) BM 
chimeras demonstrates that it is still possible to identify a 
CLN counterpart for each of the five DC subsets identified 
within the dermis (Table I).
The relative representation of the five skin-derived DC 
subsets present within CLNs differs from that found in the 
dermis (Table I). In CLNs, CD207 CD11b and CD207 
CD11b+ mDDCs corresponded to 20.8 and 35.2% of skin-
derived DCs, respectively, whereas CD207+ CD103+ and 
CD207+ CD103 mDDCs corresponded to 13.5 and 7.0%, 
of skin-derived DCs, respectively. CD207+ CD103 mLCs 
Upon migration to the CLNs, F4/80 expression was down-regulated on mLCs and CD207 mDDCs. If we except mLCs that showed a slight decrease in 
Sirp levels, Sirp expression was up-regulated or induced on all the remaining skin-derived migratory DC subsets. Data shown are representative of at 
least six chimeric mice corresponding to three independent experiments.
 
Table I.  Phenotype and frequency of the five skin DC subsets prior to and following their migration to CLNs
Skin subset Phenotypes Frequency
%
Epidermis
  Epidermal LCs CD207++, CD11bint, CD103, EpCAM++, CD24+, Sirp+  100 ± 1
Dermis
  LCs in transit CD207++, CD11bint, CD103, EpCAM++, CD24+, Sirp+ 6.4 ± 1
  CD207+ CD103 DDCs CD207+, CD11blow, CD103, EpCAM/low, CD24+, Sirp 2.8 ± 0.5
  CD207+ CD103+ DDCs CD207+, CD11blow, CD103+, EpCAM/low, CD24+, Sirp 2.6 ± 0.6
  CD207 CD11b DDCs CD207, CD11b/low, CD103, EpCAM, CD24, Sirplow 16.3 ± 1.3
  CD207 CD11b+ DDCs CD207, CD11bhigh, CD103, EpCAM, CD24, Sirp+ 65.8 ± 5
CLNs
  mLCs CD207+, CD11b/low ↓, CD103, EpCAM+, CD24+, Sirp+ 9.5 ± 2.9
  CD207+ CD103 mDDCs CD207+, CD11b/low, CD103, EpCAM+ ↑, CD24+, Sirp+ ↑ 7.0 ± 4.2
  CD207+ CD103+ mDDCs CD207+, CD11b/low, CD103+, EpCAM+ ↑, CD24+, Sirplow 13.5 ± 4.5
  CD207 CD11b mDDCs CD207, CD11b, CD103bim ↑, EpCAMbim ↑, CD24bim ↑, Sirp+ ↑ 20.8 ± 2.5
  CD207 CD11b+ mDDCs CD207, CD11b+, CD103bim ↑, EpCAMint ↑, CD24int ↑, Sirp+ 35.2 ± 2.6
The percentage ± SEM of each subset among MHCII+ (epidermis and dermis) or MHCIIhigh CD11cinter-to-high (CLN) cells were calculated from at least six independent experiments. 
Upward and downward pointing arrows indicate markers that were up-regulated or down-regulated, respectively, upon migration to CLNs. Bim, bimodal.194 Function of skin DC subsets | Henri et al.
CD207+ mDDCs were CD103. Therefore, congruent with 
a recent study (Shklovskaya et al., 2008), our data show that 
CD103 expression does not permit the unequivocal discrimi-
nation of CD207+ DCs of epidermal and dermal origin be-
cause a substantial fraction of the CD207+ mDDCs is CD103 
and will therefore contaminate the CD103 mLC fraction. 
Moreover, CD103 was induced on 15.3 and 9.4% of the 
CD207 CD11b and CD207 CD11b+ mDDCs, respec-
tively (Fig. 3 B), an observation which is particularly relevant 
for the functional studies that are described in a subsequent 
section. Therefore, at present, the only way to discriminate 
between mLCs and CD207+ CD103 mDDCs present in 
CLNs is through the use of BM chimeras.
Proliferation and turnover of the five skin DC subsets  
before and after their migration to CLNs
The five distinguishable skin DC subsets were analyzed be-
fore and after their migration to CLNs for the expression of 
Ki-67, a nuclear protein specifically expressed in cells which 
are actively cycling (Fig. 4 and Fig. S5). Approximately 10% 
of epidermal LCs were Ki-67+, and this percentage dropped 
accounted for 9.5% of the skin-derived DCs. The difference 
existing in the representation of those different DC subsets 
between the dermis and CLNs could reflect a different rate of 
migration from the skin or survival within the CLNs. Alto-
gether,  the  MHCIIhigh  CD11cinter-to-high  skin-derived  DCs 
present in CLNs are sevenfold more numerous than the MH-
CIIlow  CD11chigh  lymphoid  tissue–resident  DCs  (Fig.  S3). 
Furthermore, it should be noted that our MHCII-CD11c 
gating  strategy  excluded  the  lymphoid  tissue–resident 
CD207+ CD8+ DCs from the skin-derived migratory DC 
fraction(Fig. S3). Comparison of the phenotype of each skin 
DC subset before and after migration to CLNs showed that 
EpCAM expression was maintained at high levels on mLCs, 
whereas its expression increased on CD207+ mDDCs and 
was induced on CD207 mDDCs (Fig. 2).
Comparison of the expression of CD40, CD80, CD86, 
and PD-L1 (CD274) on the five skin-derived DCs after their 
migration to CLNs showed that they expressed higher levels 
of CD40, CD80, CD86, and PD-L1 at the cell surface, a 
phenotype matching that expected for mature DCs (Fig. S4). 
Akin to the situation encountered in the dermis, 31.7% of the 
Figure 3.  Draining CLNs contain five skin-derived DC subsets. Flow cytometry analysis of the skin-derived migratory DCs (MHCIIhigh CD11cinter-to-high) 
present in CLNs from C57BL/6 (B6) mice and B6 (CD45.1)→B6 (CD45.2) BM chimeras. MHCIIhigh CD11cinter-to-high DCs were analyzed for the expression of 
CD207 versus CD11b and CD103 expression determined on each of the specified DC subsets. (A) A single CD207+ CD11b/low DC cluster is present in the 
CLNs of B6 mice. Unlike DDCs, LCs are radio resistant, and this permits the use of B6 (CD45.1)→B6 (CD45.2) chimeras to split the single CD207+ CD11b/low 
DC cluster into host-derived mLCs and into CD103+ and CD103 donor-derived mDDCs. Two additional mDDC subsets with a CD207+ CD11b and 
CD207 CD11b+ phenotype can be identified in both C57BL/6 mice and B6 (CD45.1)→B6 (CD45.2) chimeras. (B) Expression of CD103 among the DC sub-
sets found in the dermis of B6 (CD45.1)→B6 (CD45.2) BM chimeras. The percentages of cells found in each of the specified gates are indicated. Data 
shown are representative of at least 12 chimeric mice corresponding to six independent experiments.JEM VOL. 207, January 18, 2010 
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Figure 4.  The five skin DC subsets proliferate before their migration to LNs. (A–C) The five skin DC subsets (A and B) and their migratory counter-
parts found in the CLNs (C) were identified using B6 (CD45.1)→B6 (CD45.2) chimeras, as specified in Figs. 1 and 3, and analyzed for Ki-67 expression. 
Lymphoid tissue–resident DCs were defined on the basis of their CD11chigh MHCIIinter phenotype (Fig. S3). Positioning of the Ki-67+ gate is based on stain-
ing with isotype control antibody (Fig. S4). Data shown are representative of three independent experiments.196 Function of skin DC subsets | Henri et al.
et al., 2002; Vishwanath et al., 2006; Poulin et al., 2007), LCs 
had a slow turnover and only 50% of them were replaced af-
ter 3 wk of BrdU treatment. Removing BrdU after 4 wk of 
continuous administration and proceeding to a 2-wk-long 
chase showed that LCs are slowly replaced by unlabeled cells, 
with this replacement occurring first in the epidermis. Both 
CD207+ CD103+ and CD207 CD11b DDCs exhibited a 
faster turnover than LCs, and 50% of them were replaced af-
ter 7 d of BrdU exposure and, furthermore, showed rapid loss 
of BrdU staining after a 2-wk-long chase. The delay that ex-
ists in the ascending part of the BrdU labeling curve corre-
sponding to the CD207+ CD103+ mDDCs present in CLN 
as compared with that of the CD207+ CD103+ DDCs pres-
ent in the skin suggests that they are related through a precur-
sor–product relationship (Fig. 5). A similar delay was also 
found for CD207 CD11b DDCs, the turnover of which 
was intermediate between the fast and the slow turnover 
to 6% in the mLCs that are present in transit in the dermis 
and to 1% in the mLCs found in CLNs (Fig. 4, A–C). In the 
dermis, the highest levels of Ki-67 expression were found in 
the CD207+ CD103+ (17%) and CD207 CD11b (21.5%) 
subsets, with the CD207+ CD103 and CD207 CD11b+ 
subsets showing 13.6 and 10.3% Ki-67+ cells, respectively. In 
CLNs, 11% of the lymphoid tissue–resident DCs were Ki-
67+, whereas, at most, 1.2% of the skin-derived DC subsets 
expressed Ki-67. Therefore, the five identified DC subsets 
proliferate to a different extent when localized in the skin and 
largely lose this potential upon migration to the CLNs, a fea-
ture which permits us to perform, as shown in the subsequent 
paragraph, appropriate BrdU labeling experiments.
To determine the turnover of the five skin DC subsets 
before and after their migration to CLNs, B6 (CD45.1)→B6 
(CD45.2) chimeras were continuously exposed to BrdU for 
up to 4 wk (Fig. 5). Consistent with previous data (Kamath 
Figure 5.  Comparison of the BrdU-labeling kinetics of the five distinct skin DC subsets before and after their migration to CLNs. BrdU was 
administered continuously for 28 d to a group of two B6 (CD45.1)→B6 (CD45.2) chimeric mice. After 28 d of continuous BrdU administration, a group of 
B6 (CD45.1)→B6 (CD45.2) chimeras was kept without BrdU and analyzed 2 wk later (2-wk chase). DC subsets were defined as described in Figs. 1 and 3, 
and the percentage of BrdU+ cells was determined. Data shown are representative of three independent experiments. Positioning of the positive gate is 
based on staining with isotype control antibody (not depicted). Error bars correspond to the SEM.JEM VOL. 207, January 18, 2010 
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observed for CD207+ CD103+ DDCs and LCs, respectively. 
Unexpectedly, the CD207 CD11b+ DDCs found in the 
dermis showed a slower rate of BrdU incorporation than the 
CD207 CD11b+ mDDCs found in CLNs. As analyzed in 
the Discussion section, such discrepancy is likely a result of 
the fact that the CD207 CD11b+ DDCs present in the der-
mis include CD11c cells that are MHCIIhigh CD11b+. Alto-
gether, these data show that most DDCs have fast labeling 
kinetics that are only slightly slower than those of lymphoid 
tissue–resident DCs (Liu et al., 2007). Moreover, the initial 
lag in BrdU labeling observed for most of the distinguishable 
subsets between their skin and CLN counterparts likely cor-
responds to the time taken by the BrdU-labeled cells to mi-
grate from the skin to the CLNs.
Mature DCs from E-deficient mice express  
Y-Ae–recognizable pMHCII complexes
It has been suggested that LCs in transit to CLNs can transfer 
the antigens they have captured in the epidermis to the DDCs 
that continuously crawl through the interstitial space of the 
dermis (Ng et al., 2008). Such exchanges may amplify im-
mune  responses  by  recruiting  more  skin-derived  DCs  to 
present antigens in CLNs (Villablanca and Mora, 2008). To 
demonstrate that CD207+ and CD207 DDCs can capture 
LC-derived antigens and subsequently convey them to CLNs 
under steady-state conditions, Ginhoux et al. (2007) took ad-
vantage of the specificity of the Y-Ae monoclonal antibody. 
Y-Ae  recognizes  peptide–MHCII  (pMHCII)  complexes 
made of I-Ab molecules and of a peptide corresponding to 
residues 52–68 of the I-E  chain (E52-68; Murphy et al., 
1992). F1 mice resulting from the cross of BALB/c (I-Ed+) 
mice expressing the E52-68 peptide and of B6 mice that ex-
press a null allele of the Ab gene and are thus deprived of I-Ab 
molecules were lethally irradiated and reconstituted with BM 
cells isolated from B6 Lang-EGFP mice. In these B6 Lang-
EGFP→C57BL/6 I-Ab– x BALB/c chimeras, radio-resistant 
LCs are deprived of I-Ab molecules but have the potential to 
transfer  E52-68  peptides  to  donor-derived  CD207+  and 
CD207 DDCs that are the only skin DCs that express I-Ab 
molecules. Both CD207+ and CD207 DDCs were found to 
be positive for Y-Ae, a feature thought to establish their ca-
pacity to capture and present the LC-derived E52-58 peptide. 
Based on those results it was concluded that, under steady-
state conditions, DDCs interact with mLCs in the dermis and 
migrate to the CLNs laden with LC-derived antigenic pep-
tides (Ginhoux et al., 2007).
Although B6 mice express I-Ab molecules, they do not 
have a functional I-E gene (Mathis et al., 1983) and cannot 
generate E52-68–I-Ab complexes. As a result, their B cells 
show  no  detectable  Y-Ae  staining.  However,  upon  LPS 
treatment, activated B cells from B6 mice stain with Y-Ae 
(Viret and Janeway, 2000). This unexpected reactivity de-
pends on the expression of the MHCII exchange factor H-
2M and thus corresponds to the recognition of pMHCII 
complexes involving I-Ab and endogenous peptides distinct 
from E52-58 (Viret and Janeway, 2000). Furthermore, Y-Ae 
was also found to be capable of staining mature DCs present   
in late cultures of B6 BM progenitors (Viret and Janeway, 2000). 
This prompted us to determine whether Y-Ae–recognizable   
epitopes can be found on skin DCs that originate from B6 
mice and that have matured under physiological in vivo   
conditions, a key control which was not included in the ex-
periments of Ginhoux et al. (2007). Therefore, we compared 
Y-Ae expression on the various skin-derived DCs of B6 mice 
before and after their migration to CLNs (Fig. 6 A). Consis-
tent with their capacity to coexpress E52-68 peptides and   
I-Ab molecules, mLCs, CD207+, CD207 CD11b, and 
CD207  CD11b+  mDDCs  isolated  from  CLNs  of  B6  x 
BALB/c F1 mice displayed high levels of Y-Ae staining and 
their immature precursors present in the skin also exhibited 
strong Y-Ae staining (Fig. 6 A). The level of Y-Ae staining 
was, however, higher on the skin-derived DC subsets iso-
lated from the CLNs of B6 x BALB/c F1 mice as compared 
with their dermal counterparts, a finding which is consistent 
with the fact that upon migration to CLNs, skin-derived 
DCs express up-regulated levels of MHCII and enhanced   
antigen-processing activity (Kissenpfennig et al., 2005b; Spörri 
and Reis e Sousa, 2005; Jiang et al., 2007). As expected, DCs 
isolated from the skin and CLNs of I-Ab–negative BALB/c 
mice showed no Y-Ae staining (unpublished data). Although 
LCs,  CD207+,  CD207  CD11b,  and  CD207  CD11b+ 
DDCs isolated from the skin of E52-68-negative B6 mice 
showed no detectable staining with Y-Ae, their mature de-
rivatives isolated from steady-state B6 CLNs showed readily 
detectable Y-Ae reactivity (Fig. 6 A). Importantly, the ho-
mogeneous density distribution of Y-Ae staining displayed 
by those mature DC subsets was markedly lower than that 
observed  on  the  corresponding  DC  subsets  isolated  from 
CLNs of mice expressing E52-68–I-Ab complexes. There-
fore, the observations of Viret and Janeway (2000) also apply 
to in vivo conditions in that Y-Ae–recognizable epitopes are 
readily detectable on mLCs, CD207+, CD207 CD11b, 
and CD207 CD11b+ mDDCs that are found in steady-state 
CLNs of mice that express I-Ab molecules in the absence of 
E chains and, thus, of E52-68 peptides. The absence of de-
tectable Y-Ae staining on immature skin DCs from B6 mice 
is likely a result of their lower expression of MHCII mole-
cules or of those endogenous peptides that confer Y-Ae reac-
tivity once bound to I-Ab.
DDCs do not capture LC-derived E52-68 peptides
The results mentioned in the previous section suggest that 
the low levels of Y-Ae reactivity observed by Ginhoux et al. 
(2007) on CD207+ mDDCs present in the CLNs of B6 Lang-
EGFP→C57BL/6 I-Ab– x BALB/c chimeras might not re-
sult  from  the  capture  of  LC-derived  E52-68  peptides  but 
might correspond to the expression of I-Ab molecules bound 
to endogenous peptides. To validate this alternative hypoth-
esis, F1 mice resulting from the cross of BALB/c mice and of 
B6  mice  deprived  of  MHCII  molecules  (B6  MHCII/; 
Madsen et al., 1999) were lethally irradiated and reconsti-
tuted  with  BM  cells  isolated  from  Lang-EGFP  (CD45.1) 198 Function of skin DC subsets | Henri et al.
Figure 6.  DDCs do not present E52-68 LC-derived peptides. (A) Flow cytometry analysis of LCs, CD207+, CD207 CD11b, and CD207 CD11b+ 
DDCs isolated from Langerin-EGFP→B6 MHCII/ x BALB/c chimeras (red) and from B6 (green) and B6 x BALB/c (blue) mice before (skin) and after (CLN) 
their migration to CLN. Cells were separately stained with Y-Ae and isotype control staining (CTRL). (B) CD11c+ DCs isolated from B6 and B6 x BALB/c mice 
were cultured together with H30 T cells in the presence or absence of 3 µg/ml E52-68 peptide. The content of IL-2 present in supernatant was determined JEM VOL. 207, January 18, 2010 
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mice. In these chimeras, LCs are deprived of I-Ab molecules 
but will have the potential to transfer E52-68 peptides to 
DDCs.  LCs,  CD207+,  CD207  CD11b,  and  CD207 
CD11b+  DDCs  isolated  from  the  skin  of  Lang-EGFP 
(CD45.1)→B6 MHCII/ x BALB/c (CD45.2) chimeras 8 
wk after reconstitution showed no detectable staining with 
Y-Ae (Fig. 6 A). In contrast, CD207+, CD207 CD11b, 
and CD207 CD11b+ mDDCs isolated from the CLNs of 
Lang-EGFP (CD45.1)→B6 MHCII/ x BALB/c (CD45.2) 
showed levels of Y-Ae staining that, although lower than 
those  observed  on  the  corresponding  DC  subsets  isolated 
from B6 x BALB/c F1 mice, were identical to those isolated 
from E52-68-negative B6 mice (Fig. 6 A).
To  formally  demonstrate  that  the  low  levels  of  Y-Ae 
staining  observed  on  CD207+,  CD207  CD11b,  and 
CD207 CD11b+ mDDCs isolated from the CLNs of Lang-
EGFP (CD45.1)→B6 MHCII/ x BALB/c (CD45.2) chi-
meras do not involve E52-68 peptides, we analyzed whether 
they were capable of stimulating T cells specific for E52-68–
I-Ab complexes. In contrast to the Y-Ae antibody, 1H3.1, a 
T cell hybridoma derived from a B6 mouse immunized with 
E52-68 peptides (Rudensky et al., 1991a,b), and H30 T cells, 
which result from transfection of the TCR- and TCR- 
chains of 1H3.1 into a TCR-negative T cell hybridoma vari-
ant, display an exquisite specificity for E52-68–I-Ab com-
plexes  present  at  the  surface  of  DCs  derived  from  B6  x 
BALB/c  F1  CLNs  (Fig.  6  B;  Viret  and  Janeway,  2000). 
When CD207+, CD207 CD11b, and CD207 CD11b+ 
mDDCs isolated from Lang-EGFP (CD45.1)→B6 MHCII/ x 
BALB/c (CD45.2) CLNs were cultured in the presence   
of 1H3.1 or H30 T cells, none of them were capable of 
eliciting the production of IL-2, supporting the view that the 
low levels of Y-Ae reactivity they displayed do not involve 
the E52-68 peptide (Fig. 6 C). Pulsing CD207+, CD207 
CD11b, and CD207 CD11b+ mDDCs with E52-68 pep-
tides conferred upon them the ability to activate 1H3.1 and 
H30 T cells (Fig. 6 C). Therefore, the DC isolation procedure 
fully preserved their ability to stimulate T cells. Importantly, 
when B6 splenocytes were pulsed with decreasing amounts of 
E52-68 peptide, 1H3.1 and H30 T cells were capable of pro-
ducing IL-2, even at peptide doses that do not generate a 
detectable signal after staining with Y-Ae (Viret and Janeway, 
2000). Therefore, these results cannot be accounted for by the 
poor sensitivity of 1H3.1 T cells, and they demonstrate that 
the presence of E52-68-independent Y-Ae–recognizable epit-
opes at the surface of the mature skin-derived DCs found in 
the  CLNs  of  Lang-EGFP  (CD45.1)→B6  MHCII/  x 
BALB/c (CD45.2) prevent reaching any conclusion on the 
capacity of DDCs to capture LC-derived peptides and to 
convey them to CLNs.
CD207+ CD103+ DDCs cross-present  
keratinocyte-derived antigens
To determine the relative ability of the five skin DC subsets 
to cross-present self antigens expressed in keratinocytes, we 
used the K5.mOVA transgenic mouse model, in which a por-
tion of the ovalbumin protein (OVA) is fused to the trans-
membrane  domain  of  the  transferrin  receptor  to  provide 
membrane localization and expressed under the control of 
the K5 keratin promoter (Azukizawa et al., 2003). Earlier 
studies have established that both mLCs and mDDCs were 
capable of cross-presenting OVA and of triggering the prolif-
eration of OT-I CD8+ T cells that were specific for H-2Kb–
OVA complexes (Azukizawa et al., 2003; Waithman et al., 
2007). The  involvement  of  LCs  in  cross-presentation  was 
likely a result of the fact that earlier studies were unaware of 
the existence of CD103+ DCs that also expressed CD207, 
and a recent study showed that CD103+ mDDCs isolated 
from the CLNs of K5.mOVA mice constitute the only skin-
derived DCs capable of cross-presenting OVA (Bedoui et al., 
2009).  Importantly,  the  elegant  sorting  scheme  used  by 
Bedoui et al. (2009) to reach such conclusions did not take 
into account the presence of CD103+ cells among CD207 
CD11b+ and CD207 CD11b mDDCs (Fig. 3 C). There-
fore, to prevent the contamination of CD207+ CD103+  
mDDCs by those CD207 CD11b+ and CD207 CD11b 
mDDCs that express CD103, we developed a sorting scheme 
allowing the isolation of homogeneous populations of CD207 
(EGFP)+ CD103+, CD207CD11b, and CD207CD11b+ 
mDDCs  from  the  CLNs  of  Lang-EGFP  K5.mOVA  mice 
(Fig.  7  A).  Our  sorting  scheme  also  yielded  a  fourth 
CD207+CD103 fraction that comprises mLCs as well as 
CD207 (EGFP)+CD103 mDDCs. To analyze their respec-
tive capacity to cross-present OVA expressed by keratinocytes, 
each of the sorted subsets was cultured at various ratios with 
CFSE-labeled OT-I CD8+ T cells. After 60 h of culture, the 
magnitude  of  OT-I  proliferation  was  assessed.  CD207+ 
CD103+ mDDCs constituted the sole subset capable of cross-
presenting OVA (Fig. 7, B and C). As expected, DC subsets 
sorted from Lang-EGFP mice did not induce any OT-I pro-
liferation (Fig. 7 C), but upon incubation with the OVA257-
264 peptide all the sorted DC subsets were able to induce 
OT-I proliferation (Fig. S6). The induction of granzyme was 
also analyzed, and CD207+ CD103+ mDDCs isolated from 
the CLNs of Lang-EGFP K5.mOVA mice were again the 
only DC population capable of inducing granzyme A (un-
published data). Consistent with previous studies (Waithman 
et al., 2007), OVA expressed in keratinocytes was not cross-
presented by CD11chigh MHCIIinter lymphoid tissue-resident 
DCs (unpublished data). Therefore, even when depleted of 
contaminating  CD207  CD11b+  CD103+  and  CD207 
after 24 h of culture. (C) LCs, CD207+, CD207 CD11b, and CD207 CD11b+ DDCs isolated from the CLNs of Langerin-EGFP→B6 MHCII/ x BALB/c chi-
meras were cultured together with H30 T cells that are specific for E52-68–I-Ab complexes and in the presence or absence of 3 µg/ml E52-68 peptide. The 
content of IL-2 present in supernatant was determined after 24 h of culture. Data shown are representative of three independent experiments. Error bars 
correspond to SEM.
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Figure 7.  CD207+ CD103+ mDDCs cross-present a keratinocyte-derived self antigen. (A) Gating strategy for isolation of CD207+ CD103+, CD207 
CD11b, and CD207 CD11b+ mDDCs from Lang-EGFP K5.mOVA and Lang-EGFP CLNs. Skin-derived DCs were identified on the basis of their MHCIIhigh 
CD11cinter-to-high phenotype. Expression of CD207 (EGFP) and CD11b was assessed among MHCIIhigh CD11cinter-to-high DCs, leading to the isolation of CD207 
CD11b/low and CD207 CD11b+ mDDCs. CD207+ cells were categorized on the basis of CD103 expression. CD207+ CD103+ cells corresponded to CD207+ JEM VOL. 207, January 18, 2010 
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CD103+ mDDCs, whereas CD207+ CD103 cells corresponded to a mix of mLCs and CD207+ CD103 mDDCs. (B) DC subsets, sorted according to the 
scheme described in A, were cultured with CFSE-labeled OT-I transgenic T cells. Histograms corresponding to CFSE dilution are shown after gating on cells 
that stain positive with H-2Kb-OVA257-264 tetramers. (C) The absolute numbers of divided OT-I transgenic T cells, in response to DC subsets sorted from 
Lang-EGFP K5.mOVA or Lang-EGFP CLNs, are presented. Data are representative of three independent experiments.
 
CD11b CD103+ cells, CD207+ CD103+ mDDCs remain 
the only skin migratory DCs capable of cross-presenting a 
keratinocyte-derived antigen.
LCs are dispensable for cross-presentation of keratinocyte-
specific antigen by CD207+ DDCs
Considering that LCs are closely intermingled with keratino-
cytes (Kissenpfennig et al., 2005b), it is possible that mLCs 
transferred OVA to the CD207+ CD103+ DDCs, thereby 
allowing them to play a dominant role in the cross-presenta-
tion of keratinocyte-expressed OVA. To determine whether   
CD207+ CD103+ DDCs do require the help of LCs to cross-
present keratinocyte-expressed OVA, we used Lang-DTREGFP x   
B6 K5.mOVA mice in which LCs and CD207+ DDCs are 
equally sensitive to DT treatment and can thus be chronically 
depleted by systemic administration of DT (Kissenpfennig   
et al., 2005b). After in vivo DT treatment, LCs and CD207+ 
DDCs repopulate the skin with different kinetics. For in-
stance, CD207+ DDCs reappear in the dermis as soon as 3–4 d 
after DT administration, whereas epidermal LCs are unde-
tectable for up to 20 d after DT administration (Bursch et al., 
2007; Poulin et al., 2007; Wang et al., 2008). Therefore, we 
took advantage of such distinct kinetics of reappearance to 
assess whether CD207+ DDCs constitute the main subtype 
able to cross-present keratinocyte-derived OVA in vivo and 
perform this exclusive task irrespective of the presence of 
LCs. A  group  of  Lang-DTREGFP  x  B6  K5.mOVA  mice 
received a last DT injection 13 d before adoptive transfer of 
CFSE-labeled OT-I T cells (DT -13 mice; Fig. 8 A). At the 
time of OT-I T cell transfer, such timing of DT administration 
resulted in the complete elimination of LCs for >2 wk but 
allowed the reconstitution of the CD207+ DDC compart-
ment in both the dermis and the CLNs (Fig. 8 B). We also 
prepared Lang-DTREGFP x B6 K5.mOVA mice that received 
a last DT injection 1 d before transfer of CFSE-labeled OT-I 
CD8+ T  cells,  a  protocol  which  depletes  both  LCs  and 
CD207+ DDCs at the time of OT-I T cell transfer (DT -1 
mice; Fig. 8, A and B). Upon transfer into B6 control mice, 
OT-I T cells did not show any sign of proliferation (Fig. 8 C, 
left). In contrast, OT-I T cells robustly proliferated upon trans-
fer into untreated Lang-DTREGFP x B6 K5.mOVA mice 
and a proliferation of the same magnitude occurred upon 
transfer  in  Lang-DTREGFP  x  B6  K5.mOVA  mice  that 
received a last DT injection on day 13 before transfer of 
CFSE-labeled OT-I T cells (Fig. 8 C). In contrast, in Lang-
DTREGFP x B6 K5.mOVA mice that received a last DT in-
jection on day 1 before transfer of CFSE-labeled OT-I T 
cells, both the percentage of dividing OT-I T cells and the 
yield of OT-I T cells were dramatically decreased (Fig. 8, C 
and D). Altogether, these results demonstrate that CD207+ 
DDCs are the dominant skin-migratory subtype capable of 
cross-presenting an antigen whose expression is limited to 
keratinocytes. Moreover, mLCs do not need to ferry OVA 
into the dermis to make it available to CD207+ DDCs.
DISCUSSION
We identified up to five different DC subsets in mouse steady-
state dermis by combining CD207, CD11b, and CD103 expres-
sion, with one of those subsets corresponding to epidermal LCs 
in transit to CLNs. A similar analysis performed in steady-state 
CLNs revealed the presence of a smaller number of skin-derived 
DC subsets. This is a result of the fact that CD11b expression 
loses its discriminatory power in the CLNs and does not permit 
mLCs to be distinguished from CD207+ mDDCs. Regardless of 
this technical limitation, analysis of B6 (CD45.1)→B6 (CD45.2) 
BM chimeras demonstrated that CLNs do contain a counterpart 
of each of the five different DC subsets identified in the dermis. 
Note that the bimodal CD103 expression found on both 
CD207 CD11b+ and CD207 CD11b mDDC subsets can 
be further used to distinguish up to seven skin-derived DC sub-
sets within steady-state CLNs. In a few studies, CD45+ dermal 
cells have been divided into CD11c+ CD11b-to-+ and CD11c 
CD11b+ subsets (Bogunovic et al., 2006; Jakubzick et al., 2008).   
The  CD11c+  CD11b-to-+  subset  expresses  high  levels  of 
MHCII molecules and corresponds to DDCs (Jakubzick et al., 
2008). The CD11c CD11b+ subset likely corresponds to der-
mal  macrophages  (Dupasquier  et  al.,  2004;  Jakubzick  et  al., 
2008). However, a fair fraction of it also expresses high levels of 
MHCII molecules and has been categorized as DDCs in some 
studies (Jakubzick et al., 2008) but not others (Bogunovic et al., 
2006). The enzymatic treatment required to prepare epidermal 
and dermal cell suspensions complicates the usage of the CD11c 
marker (Stutte et al., 2008) and led us to limit its usage to the 
characterization of the DCs found in CLNs. Accordingly, the 
CD207 CD11b+ subset present within our CD45+ MHCIIhigh 
dermal cells likely includes both CD11c+ CD11b+ and CD11c 
CD11b+ cells. In the case that MHCIIhigh CD207 CD11c 
CD11b+ cells correspond to dermal macrophages (Bogunovic   
et al., 2006), they are expected to have a low rate of BrdU labeling 
and to reside permanently in the dermis. Therefore, the presence 
of those last cells in the dermis and only in the dermis likely   
accounts for the inconsistency in the BrdU incorporation rate 
noted for the CD207 CD11b+ subset found in the skin and in 
the CLNs. Settling this important issue will require the identifi-
cation of specific markers allowing us to discriminate DDCs 
from dermal macrophages.
Because of the lack of appropriate cell surface markers, it is 
impossible to discriminate mLCs from CD207+ mDDCs in 
nonchimeric mouse CLNs. However, the distinct repopulation 
kinetics of LCs and of CD207+ DDCs that follow DT treatment 202 Function of skin DC subsets | Henri et al.
Figure 8.  CD207+ CD103+ mDDCs cross-present a keratinocyte-derived self antigen regardless of the presence of mLCs. (A) Experimental 
scheme for the depletion of LCs alone or of both LCs and CD207+ mDDCs in Lang-DTREGFP x B6 K5.mOVA mice. 1 µg DT (open arrows) was administered 
i.p. 18 and 13 (DT–13) or 6 and 1 (DT–1) d before adoptive transfer of 5 × 106 CFSE-labeled OT-I CD8+ T cells (filled arrows). (B) Kinetics of reappearance of JEM VOL. 207, January 18, 2010 
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the various skin (epidermis and dermis) or skin-derived (CLN) DC subsets after DT ablation. DCs from DT–13 and DT–1 Lang-DTREGFP x B6 K5.mOVA mice 
were gated as MHCII+ (epidermis and dermis) and MHCIIhigh CD11cinter-to-high (CLNs) cells and then analyzed using CD207-MHCII (epidermis) and CD207)-
CD11b (dermis and CLN) dot plots. Untreated Lang-DTREGFP x B6 K5.mOVA (no DT) mice are also shown. Windows correspond to LCs (epidermis) and to 
mLCs, CD207+ DDCs, CD207 CD11b, and CD207 CD11b+ (dermis). In the CLNs, windows correspond to CD207 CD11b, CD207 CD11b+, and mLCs + 
CD207+ DDCs. Numbers indicate the percentage of cells in the specified windows. (C and D) 60 h after adoptive transfer in the specified mice, the OT-I 
CD8+ T cells present in pooled skin-draining LNs were analyzed by flow cytometry for the percentage (C) and yield (D) of proliferating OT-I CD8+ T cells. 
Numbers in C indicate percent proliferated cells ± SEM. Data shown are representative of three independent experiments.
 
provide an opportunity to analyze the response to OVA ex-
pressed in keratinocytes when only LCs were absent or when 
both LCs and CD207+ DDCs were absent. DT administration 
1  d  before  adoptive  transfer  of  OT-I T  cells  into  Lang-
DTREGFP x B6 K5.mOVA mice resulted in the depletion of 
both LCs and CD207+ DDCs and in dramatically reduced 
response against OVA. Considering that the CD207+ CD103+ 
mDDCs isolated from the CLNs of K5.mOVA mice are the 
only DC subset that can cross-present OVA in vitro, it is para-
doxical to see that low levels of proliferation still occurred 
among  the  OT-I  T  cells  that  were  transfered  into  Lang-
DTREGFP x B6 K5.mOVA mice 1 d after DT treatment. 
Such residual T cell proliferation might be proper for the Lang-
DTREGFP x B6 K5.mOVA model and result from the fact 
that  by  undergoing  apoptosis,  the  DT-sensitive  CD207+ 
CD103+ mDDCs present in CLNs release their OVA content 
and thereby confer some adventitious cross-presentation abil-
ity to the quantitatively major CD207 migratory DCs that 
are DT resistant and present in the CLNs. When DT was ap-
plied 13 d before adoptive transfer of OT-I T cells into Lang-
DTREGFP x B6 K5.mOVA mice, OT-I T cell proliferation 
was unaffected, suggesting that the CD207+ DDCs that have 
fully reappeared at that time play a predominant role in cross-
presenting a model antigen whose expression is limited to kera-
tinocytes. Among the skin DC subsets sorted from K5.mOVA 
CLNs, CD207+ CD103+ mDDCs were the only cells capable 
of cross-presenting OVA ex vivo and are likely responsible for 
OT-I T cell activation in Lang-DTR-EGFP K5.mOVA mice 
that were DT-treated 13 d before adoptive transfer of OT-I T 
cells. Therefore, as previously shown in the case of contact 
hypersensitivity (Bennett et al., 2007; Bursch et al., 2007), 
CD207+  CD103+  mDDCs  and  mLCs  appear  to  be  en-
dowed  with  distinct  immune  functions.  Importantly,  the 
unique ability of CD207+ CD103+ mDDCs to cross-pres-
ent a keratinocyte-derived antigen is not associated with 
the expression of increased levels of CD40, CD80, CD86, 
PD-L1, and MHCII molecules. Akin to K5.mOVA mice, 
K14 mice also express OVA in keratinocytes and, upon ex-
traction from the epidermis, their LCs were found to be ca-
pable of cross-presenting OVA as assessed using OT-I T cell 
proliferation (Stoitzner et al., 2006; Bursch et al., 2009). 
Therefore, provided that the use of the K14 and K5 pro-
moters does not result in gross differences in the levels of 
OVA expression, our data and those of Bedoui et al. (2009) 
suggest that epidermal LCs lose such property upon migra-
tion to CLNs.
The possibility for CD207+ DDCs to capture an antigen 
whose expression is limited to keratinocytes in the absence of 
LCs constitutes an unexpected finding. Considering that LCs 
maintain tight contacts with keratinocytes and that the basal 
membrane found at the dermoepidermal junction insulates 
keratinocytes from DDCs, LCs might have captured OVA 
and, upon migration to the dermis, transferred it to DDCs. 
LCs are, however, dispensable for the cross-presentation ob-
served in the K5-mOVA model, and it thus remains to be de-
termined how CD207+ CD103+ DDCs can acquire OVA 
from  keratinocytes.  Furthermore,  it  has  been  noted  that 
CD207+ DDCs are often found adjacent to hair follicles (Bursch 
et al., 2007; Poulin et al., 2007) and that in rare instances, 
CD207+ DDCs were even found interdigitating with follicu-
lar epidermis (Bursch et al., 2007). Whether such anatomical 
localization favors a preferential access to OVA and accounts 
for the fact that CD207+ DDCs constitute the dominant skin-
migratory  subtype  capable  of  cross-presenting  antigen  ex-
pressed by keratinocytes remains, however, to be determined. 
It should be also noted that DCs found in the lamina propria 
of the small intestine can constitutively transport apoptotic 
epithelial cells to the mesenteric LNs (Huang et al., 2000), a 
property which might correlate with their ability to send den-
drites through the basal membrane and the mucosal epithe-
lium to sample luminal antigens (Chieppa et al., 2006). 
Provided that mouse keratinocytes express MHCII molecules, 
it may have been expected that the CD207+ CD103+ DDCs 
would be able to acquire E peptides from keratinocytes   
of Lang-EGFP B6 (CD45.1)→B6 MHCII/ x BALB/c 
(CD45.2) chimeras and to cross-present them. The genotype 
of the recipient and of the transplanted BM cells used in   
the Lang-EGFP B6 (CD45.1)→B6 MHCII/ x BALB/c 
(CD45.2) chimeras was chosen to prevent the occurrence of 
cutaneous graft-versus-host reaction and, consistent with this 
expectation, analysis of the skin of those chimeras 8 wk after 
BM transplantation revealed no signs of inflammation. Be-
cause resting keratinocytes are normally MHCII-negative and 
only express MHCII molecules during cutaneous graft-ver-
sus-host reaction (Breathnach and Katz, 1983), it is thus likely 
that, at the time of analysis, the keratinocytes of Lang-EGFP 
(CD45.1)→B6  MHCII/  x  BALB/c  (CD45.2)  chimeras 
were E negative, an attribute accounting for the fact that the 
CD207+ CD103+ mDDCs were unable to trigger T cells spe-
cific for Ea52-68-Ab pMHCII complexes.
Lymphoid tissue–resident CD8+ DCs have become a 
focus of intensive investigation because they are prone to 
cross-present antigens, a property important for inducing pe-
ripheral  tolerance  and  for  fighting  infections  and  tumors 
(Hildner et al., 2008). Interestingly, a recent study showed that 
among CD8+ splenic DCs it is the CD207+ CD103+ subset 204 Function of skin DC subsets | Henri et al.
with 2 × 106 BM cells obtained from adult B6 (CD45.1) or Lang-DTR-EGF-
PDTR (CD45.1) mice. 7–8 wk after reconstitution, the level of blood chime-
rism was determined and, at that time, >99% of blood B cells were of donor 
origin. Chimeras were kept on antibiotic-containing water (0.2% Bactrim, 
Roche, Germany) during the whole experiment.
DC  isolation.  DCs  were  isolated  from  lymphoid  organs  as  previously   
described (Vremec et al., 2000). In brief, the organs were first cut in small 
pieces and incubated with a mixture of type II collagenase (Worthington 
Biochemical Corporation) and of DNase (Sigma-Aldrich). Light density cells 
were purified by centrifugation on a Nycoprep solution (d = 1.068; Abcys). 
Skin DCs were extracted from mouse ears. In brief, ears were split in two 
parts (dorsal and ventral) and incubated overnight in PBS containing 2.5 mg/
ml dispase II (Roche) to allow separation of dermal and epidermal sheets. The 
separated epidermal and dermal sheets were then cut into small pieces and in-
cubated for 1 h at 37°C with a solution of RPMI containing 1 mg/ml DNase 
and 1 mg/ml collagenase type IV (Worthington Biochemical Corporation) to 
obtain homogeneous cell suspension. In the experiments shown in Fig. 6, 
CD11c+ DCs were purified from the specified organs using MACS.
Antibodies.  Anti-CD11c  (HL3),  anti-CD8  (53–6.7),  anti-MHCII 
(M5/114 and AF6-120.1), anti-CD45.2 (104), anti-CD45.1 (A20), anti-
CD24  (M1/69),  anti-SIRP  (P84),  anti-EpCAM,  anti-CD103  (M290), 
anti-CD5 (53–7.3), anti-Ki67, anti-CD40 (1C10), anti-CD80 (16-10A1), 
anti-CD86 (GL1), anti–PD-L1(MIH5), and anti-V2 (B20.1) antibodies 
were all purchased from BD, except for anti-CD11b (M1/70) and anti–
Ea52-68 (Y-Ae) antibodies, which were purchased from eBioscience, anti-
F4/80 antibody, which was purchased from AbD Serotec, and anti-CD207 
(929F3) antibody, which was purchased from Dendritics. H-2Kb-OVA257-264-
PE tetramers were purchased from Beckman Coulter.
Flow cytometry. Before staining, cells were preincubated on ice for at least 
10 min with the 2.4 G2 antibody to block Fc receptors. Multiparameter 
FACs analysis was performed using a FACSCanto system (BD). Analysis was 
performed using FlowJo software (Tree Star, Inc.). For each experiment, 
control mice, B6 (CD45.2), B6 (CD45.1), and Lang-DTR-EGFP mice were 
included to define the appropriate gates. Autofluorescent cells were gated 
out by using the AmCyan channel.
Sorting of DC. DCs isolated from the CLNs of Lang-EGFP x B6 K5.mOVA 
mice were stained with MHCII, CD11c, CD11b, and CD103 antibodies. 
Cells were subsequently sorted on a FACSAria system (BD). Skin-derived 
DCs (MHCIIhigh CD11clow to high) were displayed using a CD207 (EGFP) 
versus CD11b plot. CD207 DDCs were then separated into CD11b and 
CD11b+ fractions and CD207+ DCs separated into CD103 and CD103+ 
fractions. DCs isolated from the CLNs of Lang-EGFP (CD45.1)→B6 MH-
CII/ x BALB/c (CD45.2) chimeras were stained with MHCII, CD11c, 
CD11b, CD45.1, and CD103. Skin-derived DCs (MHCIIhigh CD11clow-to-high) 
were first separated into CD45.1+ and CD45.1 fractions. CD45.1 cells 
were then displayed using a CD207 (EGFP) versus CD11b plot. CD207 
DDCs were then separated into CD11b and CD11b+ fractions and CD207+ 
DCs further separated into CD103 and CD103+ fractions.
Preparation and adoptive transfer of CFSE-labeled OT-I T cells. 
OT-I T cells were purified from pooled LNs and spleen by density gradient 
using Lympholyte M followed by negative selection using a T cell isolation 
kit (Invitrogen). Purity was determined by staining with V2 and CD8 an-
tibodies. For CFSE labeling, purified OT-I T cells were resuspended in PBS 
and labeled with 2.5 µM CFSE (5- and 6-carboxy-fluorescein diacetate suc-
cinimidyl ester; Invitrogen) for 10 min at room temperature. 5 × 106 CFSE-
labeled cells were injected i.v. into the specified unirradiated recipient mice. 
60 h after injection, single-cell suspension from pooled CLNs were stained 
with PE-labeled H-2Kb-OVA257-264 tetramers and V2, CD8, and CD5 
antibodies to detect the OT-I transferred cells. The percentage and absolute 
numbers of OT-I T cells that have proliferated were determined.
that is responsible for phagocytosis of apoptotic bodies and 
for the induction of tolerance via cross-presentation of anti-
gens associated with apoptotic bodies (Qiu et al., 2009). Rest-
ing CD207+ CD103+ CD8+ DCs are located in the marginal 
zone of the spleen, a position which might facilitate the clear-
ance of circulating apoptotic cells, and they migrate to the T 
cell zone upon stimulation with microbial products (Idoyaga 
et  al.,  2009;  Qiu  et  al.,  2009). The  lung-derived  CD207+ 
CD103+ DCs that are found in the bronchial LNs are also ca-
pable of cross-presenting antigens to CD8+ T cells (del Rio   
et al., 2007). There thus exists an interesting parallel in the biol-
ogy of the CD207+ CD103+ CD8+ DCs found in the spleen 
and of the CD207+ CD103+ present in CLNs and bronchial 
LNs. It has been suggested that the special ability of CD207+ 
CD8+ DCs to cross-present antigens is a result of the fact 
that they are the only DCs to possess specialized intracellular 
machinery dedicated to cross-presentation (Schnorrer et al., 
2006; Savina et al., 2009). Such machinery might require the 
expression of langerin (CD207), a C-type lectin which par-
ticipates in the formation of Birbeck granules. However, we 
previously showed that cross-presentation is not affected in 
mice deprived of CD207 (Kissenpfennig et al., 2005a). There-
fore, the common denominator that renders these DC subsets 
prone to cross-present antigens remains to be found.
In conclusion, our data show that the quantitatively minor 
CD207+ CD103+ DDC subset has the capability of cross-pre-
senting antigens expressed by keratinocytes and that this task 
can be accomplished irrespective of the presence of LCs.   
Importantly, because of the presence in CLNs of both CD207+ 
CD103 and CD207 CD103+ mDDC subsets, we showed 
that the appropriate definition of the CD207+ CD103+ DDC 
subset requires the simultaneous analysis of CD11b, CD207, 
and CD103 expression. Our data also raise a note of caution on 
the use of the Y-Ae antibody to unravel the antigen transfers 
that may occur between distinct subsets of mature DCs. The 
possibility to identify five distinct subsets of skin DCs and their 
migratory derivatives may contribute to an understanding of 
those that pick up vaccine antigens delivered via the skin and 
initiate productive immunity rather than tolerance.
MATERIALS AND METHODS
Mice. Mice were housed under specific pathogen-free conditions and han-
dled in accordance with French and European directives. Protocols were ap-
proved by Direction Départementale des Services Vétérinaires des Bouches 
du Rhône (agreement 13–22). C57BL/6 (B6) female mice that express the 
CD45.1 (B6 [CD45.1]) or CD45.2 (B6 [CD45.2]) allele were purchased 
from Charles River. Lang-EGFP and Lang-DTREGFP mice have been pre-
viously described (Kissenpfennig et al., 2005b) and were crossed onto the B6 
(CD45.2) background for at least 10 generations. The resulting Lang-EGFP 
(CD45.2) and Lang-DTREGFP (CD45.2) mice were further crossed onto 
the B6 (CD45.1) background to obtain Lang-EGFP (CD45.1) and Lang-
DTREGFP (CD45.1) mice. MHCII/ mice backcrossed on a B6 back-
ground have been previously described (Madsen et al., 1999). B6 K5.mOVA 
mice have been previously described (Azukizawa et al., 2003). OT-I mice 
have been previously described (Hogquist et al., 1994).
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Culture of DC subpopulations with CFSE-labeled OT-I T cells. 3 × 
103 to 12 × 103 cells of each DC subpopulation were cocultured with 50 × 
103 CFSE-labeled OT-I cells in 100 µl in the presence or absence of 1 nM 
OVA257-264 peptide. After 60 h of culture, proliferation was measured by 
flow cytometry as a loss of CFSE staining.
Functional assays. The 1H3.1 T cell hybridoma derives from a B6 mouse 
immunized with the E52-68 peptide and is specific for E52-68–I-Ab com-
plexes (Rudensky et al., 1991a,b). H30 T cells result from the transfection of 
the TCR- and TCR- chains of 1H3.1 into a TCR-negative T cell hy-
bridoma variant (Viret and Janeway, 2000). H30 or 1H3.1 cells (105 cells/
well) were stimulated for 24 h with the specified DCs (104 cells/well) in the 
presence or absence of synthetic E52-68 peptide. Supernatants were har-
vested and the level of IL-2 was determined using the CTL-L cell line and 
the Cell Titer Glow Assay (Promega). Values were converted into IL-2 units 
using a recombinant mouse IL-2 standard (BD).
In vivo depletion of LCs or of CD207+ DDCs. For systemic in vivo 
depletion of CD207+ DCs, Lang-DTREGFP mice were injected i.p. with   
1 µg DT (ServiBio) using the specified timing of administration. Mice were 
analyzed at different time points after the last DT injection.
BrdU labeling in vivo and cell cycle analyses. Mice were injected i.p. with 
1.5 mg BrdU (Sigma-Aldrich) to ensure its immediate availability, and their 
drinking water was supplemented for up to 28 d with 0.8 mg/ml of BrdU and 
2% glucose and changed daily. After 28 d of continuous BrdU labeling, some 
mice received BrdU-free drinking water for an additional 2 wk and the loss of 
BrdU-positive DCs was analyzed. DCs from epidermis, dermis, and CLNs were 
first stained for surface markers and then permeabilized for BrdU staining (BrdU 
labeling Flow kit; BD) and langerin staining. Ki-67 staining (BD) was performed 
using the staining protocol corresponding to the BrdU labeling Flow kit.
Online supplemental material. Fig. S1 shows the extent of chimerism   
8 wk after BM transplantation. Fig. S2 shows that both CD207+ CD103+ and 
CD207+ CD103 DDCs can be found in the dermis of mice deprived of LCs. 
Fig. S3 shows the MHCII-CD11c contour plots of DCs found in the CLNs 
of Lang-EGFP mice. Fig. S4 shows expression of CD40, CD80, CD86, and 
PD-L1 on the five skin DC subsets before and after their migration to CLNs. 
Fig. S5 shows isotype control staining profile of the five skin DC subsets 
before and after their migration to CLNs. Fig. S6 shows OT-I proliferation 
in response to the OVA257-264 peptide. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20091964/DC1.
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